The impact of elevated serum IgA and race on primary recipient renal allograft survival

Transplantation

Volumn 61, Issue 2, 1996, Pages 205-211

  Susskind, Brian M ^a   Kerman, Ronald H ^a   Browne, Barry J ^a   Hartwell, Beth A ^a   Davis, Barbara G ^a   Katz, Stephen M ^a   Van Buren, Charles T ^a   Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A;

ARTICLE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RACE;

ADULT; CONTINENTAL POPULATION GROUPS; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOGLOBULIN A; KIDNEY TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030063661     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199601270-00007     Document Type: Article

References (38)

1. Lim EC, Terasaki PI. Outcome of kidney transplantation in different diseases. In: Terasaki PI, Cecka JM, eds. Clinical transplants 1990. Los Angeles: UCLA Tissue Typing Laboratory, 1991: 461.
2. Lim EC, Terasaki PI. Outcome of renal transplantation in different primary diseases. In: Terasaki PI, Cecka JM, eds. Clinical transplants 1991. Los Angeles: UCLA Tissue Typing Laboratory, 1992: 293.
3. Lim EC, Chia D, Gjertson DW, Koka P, Terasaki PI. In vitro studies to explain high renal allograft survival in IgA nephropathy patients. Transplantation 1993; 55: 996.
4. Koka P, Chia D, Terasaki PI, et al. The role of IgA anti-HLA class I antibodies in kidney transplant survival. Transplantation 1993; 56: 207.
5. Süsal C, Groth J, Tanzi-Fetta RF, et al. Characterization of protective anti-Fab autoantibodies in kidney graft recipients. Transplant Proc 1992; 24: 2523.
6. Süsal C, Groth J, Oberg HH, Terness P, May G, Opelz G. The association of kidney graft outcome with pretransplant serum IgG-anti-F(ab')2 gamma activity. Transplantation 1992; 54: 632.
7. Süsal C, Wiesel M, Staehler G, Groth J, May G, Opelz G. Excellent kidney graft survival in patients with high pretransplant serum IgA concentrations and IgA-anti-Fab autoantibody activity. Transplant Proc 1995; 27: 1072.
8. Killingsworth LM, Savory J. Automated immunochemical procedures for measurement of immunoglobulins IgG, IgA, and IgM in human serum. Clin Chem 1971; 17: 936.
9. Terasaki PI, Bernoco D, Park MS, et al. Microdroplet testing for HLA A, B, C and DR antigens. Am J Clin Pathol 1987; 27: 61.
10. Kerman RH, Flechner SM, Van Buren CT, et al. Successful transplantation of cyclosporine treated allograft recipients with serologically positive historical but negative preoperative donor crossmatches. Transplantation 1985; 40: 615.
11. Kerman RH, Kimball PM, Van Buren CT, et al. AHG and DTE/AHG procedure identification of crossmatch-appropriate donor-recipient pairings that result in improved graft survival. Transplantation 1991; 51: 316.
12. Buelow R, Mercier I, Glanville L, et al. Detection of panel reactive anti-HLA class I antibodies by PRA-STAT ELISA or lymphocytotoxicity: results of a blinded, controlled multicenter study. Hum Immunol 1995; 44: 1.
13. Kahan BD, Van Buren CT, Lin SN, et al. Immunopharmacological monitoring of CsA-treated kidney recipients. Transplantation 1982; 34: 36.
14. Kahan BD, Welsh M, Rutzky LA. The ability of pretransplant test dose pharmacokinetic profiles to reduce early adverse events after renal transplantation. Transplantation 1992; 53: 345.
15. Kahan BD, Revel J. Overview. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988; 46: 631.
16. Kerman RH, Kimball PM, Lindholm A, et al. Immune risk factors: impact on the incidence and diagnosis of rejection. Transplant Proc 1993; 25: 23.
17. Mitsuishi Y, Cecka JM. Disease effects and associations. In: Terasaki PI, Cecka JM, eds. Clinical transplants 1992. Los Angeles: UCLA Tissue Typing Laboratory, 1993: 371.
18. Kerman RH, Kimball P, Lindholm A, et al. Influence of HLA matching on rejections and short- and long-term primary cadaveric allograft survival. Transplantation 1993; 56: 1242.
19. Crowley-Nowick PA, Julian BA, Wyatt RJ, et al. IgA nephropathy in blacks: studies of IgA2 allotypes and clinical course. Kidney Int 1991; 39: 1218.
20. Pontier PJ, Patel TG. Racial differences in the prevalence and presentation of glomerular disease in adults. Clin Nephrol 1994; 42: 79.
21. Bodmer WF. Models and mechanisms for HLA and disease association. J Exp Med 1980; 152: 353s.
22. Zhou YC, Cecka JM, Terasaki PI. Effect of race on kidney transplants. In: Terasaki P, Cecka JM, eds. Clinical transplants 1990. Los Angeles: UCLA Tissue Typing Laboratory, 1991: 447.
23. Weiss A, Stuart FP, Fitch FW. Immune reactivity of cells from long-term rat renal allograft survivors. Transplantation 1978; 26: 346.
24. Jansen JL, Koene RA, Kamp GJ, Gerlag PG, Wijdeveld PA. Ehancement and hyperacute rejection of skin grafts in the mouse: failure to separate cytotoxic and enhancing antibodies from alloantiserum with physicochemical methods. J Immunol 1975; 114: 1557.
25. Batchelor JR, Welsh KI, Burgos H. Humoral factors. Immunologic enhancement. Transplant Proc 1977; 9: 931.
26. Voisin GA, Kinsky R, Jansen F, Bernard C. Biological properties of antibody classes in transplantation immune sera. Transplantation 1969; 8: 618.
27. Duc HT, Kinsky RG, Kanellopoulos J, Voisin GA. Biologic properties of transplantation immune sera. IV. Influence of the course of immunization, dilution and complexing to antigen on enhancing activity of Ig classes. J Immunol 1975; 115: 1143.
28. Davis WC, McKenzie IF. Immunological enhancement can be mediated by anti-Ia and anti-K, D antibodies. Transplantation 1980; 29: 77.
29. McKearn TJ, Sarmiento M, Weiss A, Stuart FP, Fitch FW. Selective suppression of reactivity to rat histocompatibility antigens by hybridoma antibodies. Curr Top Microbiol Immunol 1978; 81: 61.
30. Süsal C, Daniel V, Doerr C, Zimmermann R, Huth-Kuhne A, Opelz G. IgA-anti-Fab autoantibodies and disease progression in AIDS. Immunol Lett 1993; 36: 27.
31. Süsal C, Maier H, Lorenz K, Opelz G. Association of IgA-anti-Fab autoantibodies with disease stage in head-and-neck cancer. Int J Cancer 1994; 57: 47.
32. Süsal C, Hoffman GW, Daniel V, Grant M, Opelz G. Complementarities and network interactions in AIDS. J Autoimmun 1993; 6: 601.
33. Jerne NK. Towards a network theory of the immune system. Ann Immunol (Inst Pasteur) 1995; 125C: 373.
34. Male D. Idiotypes and autoimmunity. Clin Exp Immunol 1986; 65: 1.
35. Parker DC. Induction and suppression of polyclonal antibody responses by anti-Ig reagents and antigen-nonspecific helper factors: a comparison of the effects of anti-Fab, anti-IgM, and anti IgD on murine B cells. Immunol Rev 1980; 52: 115.
36. Phelan D, Hadley G, Duffy B, Mohanam S, Mohanakumar T. Antiidiotypic antibodies to HLA class I alloantibodies in normal individuals: a mechanism of tolerance to noninherited maternal HLA antigens. Hum Immunol 1991; 31: 1.
37. Chauhan B, Phelan D, Marsh JW, Mohanakumar T. Characterization of antiidiotypic antibodies to donor HLA that develop after liver transplantation. Transplantation 1993; 56: 443.
38. Nasu H, Chai DS, Knutson DW, Barnett EV. Naturally occurring human antibodies to the F(ab')2 portion of IgG. Clin Exp Immunol 1980; 42: 378.